FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> vaccine | Iomai

Iomai reports success with traveler’s diarrhea patch


Iomai has racked up more positive data for its vaccine patch to prevent traveler's diarrhea. A new study details that only three of 59 volunteers who used the patch experienced a severe or moderate bout of diarrhea compared to 24 of 111 who were given a placebo. The three patch users who did get sick reported that the bout lasted for only a half day. No side effects were reported.

"These results suggest that the Iomai patch has the potential to fundamentally change the way we approach prevention of this disease, an ailment against which we now have very few weapons," says Dr. Herber L. DuPont, professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health. 

Iomai recently agreed to a takeover by Intercell.

- here's Iomai's release
- read the story in CTV

Related Articles:
Intercell snaps up Iomai in $189M deal
Iomai gets boost in bird flu vaccine adjuvant study
Iomai vax patch guards against traveler's diarrhea

More stories about vaccine   Iomai  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 13 + 42?
To combat spam, please solve the math question above.